<DOC>
	<DOCNO>NCT02055820</DOCNO>
	<brief_summary>This multicenter , open-label , dose-finding study GDC-0199 administer orally combination MabThera/Rituxan ( R ) obinutuzumab ( G ) standard dos cyclophosphamide , doxorubicin , vincristine oral prednisone ( CHOP ) patient Non-Hodgkins Lymphoma ( NHL ) . Patients randomize one two treatment arm GDC-0199 combination R-CHOP G-CHOP . The study consist two stage , dose-finding stage expansion stage . The maximum tolerated dose ( MTD ) GDC-0199 combination R-CHOP G-CHOP determine dose-finding stage .</brief_summary>
	<brief_title>A Safety Pharmacokinetics Study GDC-0199 ( ABT-199 ) Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>General Patients , age &gt; = 18 year At least one bidimensionally measurable lesion define &gt; 1.5 cm long dimension Ability willingness comply study protocol procedure Confirmed availability archival freshly biopsied tumor tissue prior study enrollment ECOG performance status 0 , 1 2 Adequate hematologic function For female patient childbearing potential , agreement use highly effective form contraception Dose Escalation Portion Study : Patients must histologically confirm Bcell nonHodgkin 's Lymphoma ( NHL ) Patients must never receive previous RCHOP treatment Any relapsed/refractory patient enrol dose escalation receive single previous treatment regimen Expansion Portion Study : Patients must previouslyuntreated diffuse large , Bcell lymphoma International prognostic index ( IP ) score must 25 General Contraindication receive individual component CHOP , rituximab obinutuzumab Primary CNS lymphoma Vaccination live vaccine within 28 day prior randomization History malignancy could affect compliance protocol interpretation result Evidence significant , concomitant disease illness Use CYP3A inhibitor inducer within 7 day first dose GDC0199 Requires use Warfarin Recent major surgery Women must pregnant breastfeed Dose Escalation Portion Study : Prior anthracycline therapy Chemotherapy investigational therapy within 5 halflives biologic agent minimum 28 day prior start Cycle 1 Histologically confirm mantle cell lymphoma ( MCL ) small lymphocytic lymphoma ( SLL ) Expansion Portion Study : Patients transform lymphoma Prior therapy nonHodgkins Lymphoma ( NHL ) Current Grade &gt; 1 peripheral neuropathy Ongoing therapy calcium channel entry blocker drug therapy within 30 day C1D1 Prior radiotherapy mediastinal/pericardial region</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>